Acute Coronary Syndrome: What Is Safer, Antiaggregant Monotherapy or De-Escalation?

For several years it has been shown that 12-month dual antiplatelet therapy (DAPT) is mandatory for patients undergoing left main PCI for acute coronary syndrome (ACS). However, though this strategy does reduce thrombotic events and mortality, it also causes undesirable bleeding events followed by hospitalization and antiaggregation interruption for a period of time. 

Síndromes coronarios agudos: ¿Qué es más seguro: monoterapia con antiagregante o De-Escalation?

A feasible strategy could be to interrupt one of the antiaggregants (be it aspirin -ASA- or P2Y12 inhibitor). The alternative could be to switch (De-Escalation) to a P2Y12 inhibitor of lower antiaggregation power (for example from prasugrel or ticagrelor to clopidogrel) or to reduce dosage.

This question remains unanswered.

This meta-analysis included 29 studies with 50602 patients, and it compared short duration antiaggregation (SHORT DAPT) vs. de-escalation.

Mean age was 63, there was an important number of women and a percentage of diabetics that ranged between 22% and 26%. There were no differences in all-cause mortality. 

De-escalation reduced the risk of net adverse cardiovascular events (NACE) (RR: 0.87; 95% CI: 0.70-0.94) but increased the risk of major bleeding (RR: 1.54; 95% CI: 1.07-2.21).

Read also: IVUS in Acute Coronary Syndrome: A New Requirement?

De-Escalation showed >95% probability to prevent NACE, MI, stroke, stent-thrombosis, and minor bleeding. However, it showed a very high rate of major bleeding. 

On the other hand, the SHORT DAPT approach showed better performance (>95%) in the prevention of major bleeding.

Conclusion

In patients with acute coronary syndrome undergoing PCI there were no differences in all-cause mortality between SHORT DAPT and De-Escalation. De-Escalation reduced NACE risk, while SHORT DAPT reduced the risk of major bleeding. 

These data characterize 2 contemporary strategies to personalize the use of DAPT according to treatment goals and risk profile.

Dr. Carlos Fava - Consejo Editorial SOLACI

Dr. Carlos Fava.
Member of the SOLACI.org Editorial Board. 

Original Title: Short Duration of DAPT Versus De-Escalation After Percutaneous Coronary Intervention for Acute Coronary Syndromes.

Reference: Claudio Laudani, et al. J Am Coll Cardiol Intv 2022;15:268–277.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

AHA 2024 | VANISH2 Trial

Cardiac defibrillator implants (CDIs) have been shown to improve survival in patients with ischemic cardiomyopathy and ventricular tachycardia (VT). However, approximately one third of...

AHA 2024 | SUMMIT

It has been previously shown that the pharmacological treatment of obesity (semaglutide) can reduce cardiovascular events in patients with cardiac failure (CF) and preserved...

AHA 2024 – BPROAD

Hypertension (elevated blood pressure, BP) is the most common comorbidity among diabetic patients and has been associated with higher cardiovascular risk, though as a...

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Long Term Results of the International Chimney Registry

The International Chimney Registry was an observational study aimed at assessing the use of chimney stenting during TAVR either to predict or treat coronary...

CANNULATE TAVR extended study: Impact of Commissural and Coronary Alignment in Coronary Cannulation Following TAVR with Evolut Fx

The new valve Evolut FX has shown better commissural alignment vs. its predecessor Evolut Pro+. Prior studies have already shown commissure alignment facilitates post...

TRISCEND II: Transcatheter Replacement vs. Medical Treatment for Tricuspid Regurgitation

The EVOQUE device is designed with an intra-annular sealing system that provides excellent anatomical compatibility and an adaptable shape. It is currently available in...